Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock Has Average Target Price of $122.00

by · The Cerbat Gem

Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $122.00.

A number of research analysts recently commented on the company. Barclays reissued an “overweight” rating and issued a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. HC Wainwright upped their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. BTIG Research increased their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, UBS Group set a $125.00 price objective on Monopar Therapeutics in a research report on Thursday, July 23rd.

Read Our Latest Stock Analysis on Monopar Therapeutics

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $69.27 on Friday. The company’s fifty day moving average price is $99.83 and its 200-day moving average price is $84.11. The firm has a market capitalization of $464.94 million, a price-to-earnings ratio of -31.92 and a beta of 1.50. Monopar Therapeutics has a one year low of $50.07 and a one year high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, equities research analysts expect that Monopar Therapeutics will post -2.98 EPS for the current year.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the transaction, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 4,090 shares of Monopar Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the transaction, the director directly owned 7,396 shares in the company, valued at $823,840.44. This trade represents a 35.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 44,688 shares of company stock worth $4,023,094. 9.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently made changes to their positions in MNPR. Bank of New York Mellon Corp purchased a new position in Monopar Therapeutics in the 2nd quarter worth $7,124,000. Walleye Capital LLC purchased a new stake in Monopar Therapeutics during the first quarter valued at about $3,458,000. Siren L.L.C. boosted its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the period. Bank of America Corp DE boosted its position in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares during the period. Finally, ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares during the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.

Featured Stories